Previous 10 | Next 10 |
2024-03-27 17:44:47 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology gets $8M payment for sale of royalty rights Read the full article on Seeking Alpha For further details see: Pyxis...
2024-03-27 07:43:03 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Seeking Alpha’s Quant Rating on Pyxis Oncology ...
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEW...
2024-03-21 11:32:38 ET More on Pyxis Oncology Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Pyxis Oncology stock rises as it looks to raise $50M through a private placement Read the full article on Seeking Alpha For further ...
2024-03-21 10:12:15 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...
2024-03-21 08:43:23 ET Losers: Destination XL Group DXLG -16% after Q4 earnings release . Tourmaline Bio ( TRML ) -30% . Apyx Medical Corp APYX -17% after Q4 earnings release . Five Below FIVE -12% after Q4 earnings release . Designer Br...
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway into 2H 2026 BOSTON, March 21, 2024 (GLOBE NEWS...
2024-03-13 17:07:28 ET Gainers: Turtle Beach ( HEAR ) +22% . SoundHound ( SOUN ) +12% . Robinhood Markets ( HOOD ) +9% . Recursion Pharmaceuticals ( RXRX ) +7% . Pyxis Oncology ( PYXS ) +3% . Losers: WW International ( ...
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directo...
2024-03-08 21:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway i...